A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb 20717 in Subjects with Selected Advanced Solid Tumors (DUET-2)

Brief description of study

The primary purposes of this research study are to determine the safety and tolerability of five dose levels (0.15, 0.3, 1.0, 3.0 and 10.0 milligrams kilogram) of the investigational drug, XmAb20717, and if the XmAb20717 works in treating tumors like you have and side effects from XmAb20717, to find the maximum tolerated dose or recommended dose for treating your type of tumor. XmAb20717 is an investigational drug that is designed to activate your own cells to kill your tumor. XmAb20717 is an investigational drug in this study because it has not been approved by the U.S. Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States.


Clinical Study Identifier: s18-00049
ClinicalTrials.gov Identifier: NCT03517488
Principal Investigator: Elaine Shum
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.